IL4 and rhinitis: Dupilumab is a human monoclonal antibody that specifically blocks the alpha receptor of interleukin-4 (IL-4), inhibiting interleukin-4 and interleukin-13 signaling of these inflammatory cytokines involved in various allergic diseases, such as asthma, atopic dermatitis and rhinitis [13].